Former intern rises to CEO at Andover staffing firm Alku
Advertisement
Most of Alku's executives today, Bull said, started in entry-level positions, just like he did. That's one reason Bull says he appreciates the outside guidance provided by private equity firm New Mountain Capital, which acquired a controlling stake in Alku in 2023.
Eldridge, who picked the name Alku because it means 'start,' a staffing term, in Finnish, will stick around as an advisor to the company he founded in 2008, and will serve as chairman. The timing of the announcement coincided with his 60th birthday.
The business, located in 75,000 square feet at the Brickstone office complex in Andover, specializes in finding people to fill temporary assignments in life sciences and tech; Bull says the agency is considering whether to branch into recruiting for full-time, permanent placements, too.
Advertisement
The firm's revenue could approach $600 million this year, though the staffing industry as a whole has retrenched since hitting peak levels in 2022. As the sector contracts, Alku is gaining market share: Staffing Industry Analysts recently ranked Alku as the 41st largest based on US revenue, up from 57th the previous year, and behind only one Massachusetts-based agency, Beacon Hill Staffing Group.
Bull is the first intern to become CEO at Alku. But maybe he won't be the last.
'In my new hire orientation, I always say there's probably somebody here who will someday be certainly a vice president, or perhaps a president or CEO,' Bull said. 'I absolutely think that's within the cards. ... That's how the company has been built, from the bottom up.'
Jon Chesto can be reached at
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
37 minutes ago
- New York Post
Sen. Adam Schiff under federal criminal investigation for alleged mortgage fraud violations
Sen. Adam Schiff, D-Calif., is under criminal investigation for mortgage fraud, a Trump administration source told Fox News. Fox News host Laura Ingraham broke the news on Tuesday night on 'The Ingraham Angle,' saying the source said a criminal investigation is being conducted by the US Attorney's Office in Maryland on possible charges involving mortgage fraud. The investigation comes a month after a story broke about the Federal Housing Finance Agency (FHFA) sending a criminal referral to the Department of Justice (DOJ) alleging that Schiff, in multiple instances, falsified bank documents and property records to acquire more favorable loan terms. In a 2011 affidavit signed by the then-California congressman, Schiff certified that a property in Montgomery County, Maryland, is his primary residence. Schiff also owns a condominium in Burbank, California, which he has also claimed as his primary residence as recently as 2023, during his campaign for Senate. Schiff's office did not immediately respond to Fox News Digital's request for comment on the matter. The director of the UFHFA sent a letter to Attorney General Pam Bondi and Deputy Attorney General Todd Blanche in May citing alleged misconduct by Schiff. 'Based on media reports, Mr. Adam B. Schiff has, in multiple instances, falsified bank documents and property records to acquire more favorable loan terms, impacting payments from 2003-2019 for a Potomac, Maryland-based property,' FHFA Director William Pulte wrote in the letter. 3 A Trump administration source reported to Fox News that Sen. Adam Schiff is now being criminally investigated for mortgage fraud. Getty Images 'As regulator of Fannie Mae, Freddie Mac, and the Federal Home Loan Banks, we take very seriously allegations of mortgage fraud or other criminal activity. Such misconduct jeopardizes the safety and soundness of FHFA's regulated entities and the security and stability of the U.S. mortgage market.' Pulte later received a memo from the Fannie Mae financial crimes investigations concluding that Schiff allegedly engaged in 'a sustained pattern of possible occupancy misrepresentation' on five Fannie Mae loans, Fox News has learned. Schiff and his wife purchased a home in Potomac, Maryland, in 2003 for $870,000, according to the letter. They entered into a Fannie Mae-backed mortgage agreement for $610,000 at a rate of 5.625% over a term of 30 years, asserting the property would be their primary and principal residence. The letter said they reaffirmed that the Maryland home was their primary residence in mortgage refinancing filings in 2009, 2011, 2012 and 2013, despite Schiff being an elected official representing the state of California at the same time. 3 A letter was sent to Attorney General Pam Bondi, which details the alleged misconduct by Schiff. REUTERS Fox News obtained a copy of the 2011 affidavit showing Schiff signed certifying that the Maryland house is his primary residence. Pulte said Schiff and his wife did not list the Maryland home as their secondary residence until 2020. Over the same time frame, Schiff took a homeowner's tax exemption on a condo that he owns in Burbank, California, also claiming that home as his primary residence for a $7,000 reduction off of the 1% property tax, Pulte wrote, citing media reports. In 2023, the letter notes, a spokesperson for Schiff asserted that, 'Adam's primary residence is Burbank, California, and will remain so when he wins the Senate seat.' The federal housing official wrote that he believes Schiff's alleged misconduct could be violations of federal criminal codes banning wire fraud, mail fraud, bank fraud and false statements to financial institutions. 3 Federal Housing Finance Agency (FHFA) director William Pulte wrote in the letter that the California senator 'falsified bank documents and property records to acquire more favorable loan terms.' Getty Images Schiff 'appears to have falsified records in order to receive favorable loan terms, and also appears to have been aware of the financial benefits of a primary residence mortgage when compared to a secondary residence mortgage,' Pulte wrote. According to the letter, a spokesperson for Schiff in 2023 told CNN that, 'Adam's California and Maryland addresses have been listed as primary residences for loan purposes because they are both occupied throughout the year and to distinguish them from a vacation property.' Last year, the letter notes, a federal jury convicted Marilyn Mosby of making false statements on a mortgage application for a Florida condominium when she was the Baltimore City state's attorney. Fox News Digital's Danielle Wallace contributed to this report.
Business Upturn
an hour ago
- Business Upturn
Aurobindo Pharma share: HSBC, Motilal Oswal, Nuvama maintain ‘Buy'; Avendus retains ‘Reduce' as brokerages assess US outlook and margin risks
Shares of Aurobindo Pharma have drawn mixed reactions from top brokerages following its recent earnings performance. While HSBC, Motilal Oswal, and Nuvama continue to maintain a 'Buy' rating, Avendus has retained a more cautious 'Reduce' stance, citing near-term margin and execution risks in the US segment. Motilal Oswal on Aurobindo Pharma share: Maintains 'Buy', TP cut to ₹1,300 Motilal Oswal Financial Services has maintained its 'Buy' rating on Aurobindo Pharma but lowered the target price to ₹1,300 from ₹1,365. The brokerage noted strong growth in the EU and ARV segments but flagged continued margin pressure as a drag on profitability. EBITDA margin guidance remains unchanged at 20–21% for FY26. Motilal is optimistic about the Lanett acquisition improving profitability and expects the company to file its first US biosimilar in FY26. Earnings estimates for FY26/FY27 were cut by 8%/7% due to pricing headwinds and startup costs at Pen-G and China units. Avendus on Aurobindo Pharma share: Maintains 'Reduce', TP cut to ₹1,145 Avendus has reiterated its 'Reduce' rating with a revised target price of ₹1,145, down from ₹1,220. The firm expects US sales (excluding gRevlimid) to grow at a 9% CAGR over FY25–27E, driven by recovery in injectables and oral solids. EU revenues are expected to grow at a 14% CAGR, aided by new launches and China/Vizag-based supplies. However, the brokerage expressed concerns over delays in monetizing complex assets such as biosimilars and LA injectables, which are now expected to contribute meaningfully only post-FY28. Avendus projects a 15% EPS CAGR (ex-gRevlimid and Pen-G) through FY27 and sees the Lanett acquisition turning EPS-neutral by FY27. EPS estimates have been revised down by 9%/7% for FY26/FY27 due to lower sales and margin risks. HSBC on Aurobindo Pharma share: Maintains 'Buy', TP cut to ₹1,255 HSBC continues to maintain a 'Buy' call on Aurobindo Pharma, cutting its target price to ₹1,255. The brokerage flagged a Q1 miss driven by weaker-than-expected gRevlimid sales, US channel destocking, and pricing pressure in the API business. It highlighted Europe as a bright spot in the company's portfolio. HSBC remains constructive on future margin support from new plant supplies (Pen-G, Vizag, China) and expects volume-led growth to sustain. The brokerage is also watching for closure on the Lanett portfolio acquisition, which could add to long-term growth momentum. Nuvama on Aurobindo Pharma share: Maintains 'Buy', TP reduced to ₹1,445 Nuvama Institutional Equities has also maintained its 'Buy' rating while trimming the target price slightly to ₹1,445 from ₹1,460. The firm highlighted that gross margins remained resilient despite a decline in gRevlimid contributions. Ex-gRevlimid EBITDA margins expanded ~100 bps YoY. Key near-term triggers include the ramp-up of Pen-G and China units, MIP implementation, closure of the Lanett acquisition, and new injectable filings. Nuvama has trimmed its FY27E EPS forecast by around 2%, factoring in near-term execution risks. With varying degrees of optimism, brokerages remain focused on Aurobindo's US trajectory, biosimilar launches, and integration of recent acquisitions as key determinants of its medium-term growth story. Disclaimer: The views and investment recommendations expressed in this article are those of the respective brokerages. These do not represent the views of Business Upturn and do not constitute investment advice. Investors are advised to consult their financial advisors before making any investment decisions. Ahmedabad Plane Crash Arunika Jain, a graduate in Mass Communication, brings a fresh perspective to the world of journalism. Arunika has a passion for writing finance and corporate news at You can write to her at [email protected]
Yahoo
2 hours ago
- Yahoo
Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson's Disease
CAMBRIDGE, Mass., August 06, 2025--(BUSINESS WIRE)--Lysoway Therapeutics, Inc., a biopharmaceutical company developing small molecule modulators of lysosomal ion channels, today announced that it has received a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). Support comes from MJFF's Parkinson's Disease Therapeutics Pipeline Program, which focuses on candidates with strong potential to slow or halt disease progression or alleviate burdensome symptoms for those living with Parkinson's disease. Lysoway Therapeutics funding of $2.93 million will support the preclinical and translational development of Lysoway's novel, highly brain-penetrant small molecule TRPML1 agonist. The study aims to investigate whether activating TRPML1 by a novel, small molecule modulator, will enhance the lysosomal membrane calcium ion channel to restore lysosomal function and help with clearance of alpha-synuclein, the protein that is linked to the disease. "We are honored to receive this generous grant from The Michael J. Fox Foundation," said Valerie Cullen, PhD, Principal Investigator and SVP of Research and Translation at Lysoway. "TRPML1 is a high value target due to its pivotal role in sensing and responding to cellular stress. By activating this ion channel, we can engage multiple beneficial pathways that restore autophagy/lysosomal homeostasis and bolster cellular resilience. Our lead development candidate is both orally bioavailable and highly brain-penetrant, offering strong potential to modify disease progression in Parkinson's Disease." Yongchang Qiu, PhD, Founder and Chief Executive Officer of Lysoway Therapeutics, added "This funding underscores growing confidence in TRPML1 as a compelling target for Parkinson's disease. It will allow us to accelerate development of our lead TRPML1 agonist and to establish key biomarkers for target engagement, with the goal of initiating first-in-human clinical trials early next year." About Lysoway Therapeutics, in Cambridge, MA, Lysoway Therapeutics is a leader in developing therapeutically viable lysosomal ion channel modulators. The company is advancing a pipeline of small molecule activators targeting these channels to treat neurodegenerative diseases. Learn more at View source version on Contacts Media contact: Info@
